| [ Summary ] |
The ACTS-GC and CLASSIC trials have shown that fluoropyrimidine-based adjuvant chemotherapy improved survival rates for patients with gastric cancer after D2 gastrectomies. However, outcomes in Stage III patients have been shown to be less satisfactory. To improve results, combination chemotherapy with S-1 and cisplatin, as well as S-1 with oxaliplatin, or XELOX are encouraged. Another approach is preoperative chemotherapy, which is also being investigated although clinical benefits have not yet been established. A biomarker study to determine groups at high risk of recurrence and/or groups sensitive to adjuvant chemotherapy is warranted. |